Six-month results of suprachoroidal adipose tissue-derived mesenchymal stem cell implantation in patients with optic atrophy: a phase 1/2 study.

Creative Commons License

Oner A. , Gonen Z. , Sevim D., Sinim K., Unlu M.

International ophthalmology, vol.39, no.1, pp.2913-2922, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 39 Issue: 1
  • Publication Date: 2019
  • Doi Number: 10.1007/s10792-019-01141-5
  • Title of Journal : International ophthalmology
  • Page Numbers: pp.2913-2922


Purpose This prospective clinical case series aimed

to investigate the safety and efficacy of suprachoroidal

adipose tissue-derived mesenchymal stem cell

(ADMSC) implantation in patients with optic nerve


Methods This prospective, single-center, phase 1/2

study enrolled 4 eyes of 4 patients with optic atrophy

of various reasons who underwent suprachoroidal implantation of ADMSCs. The best-corrected visual

acuity (BCVA) in the study wasHMat 1 m. The worse

eye of the patient was operated. Patients were

evaluated on the first day, first week, first month, third

and sixth months postoperatively. BCVA, anterior

segment and fundus examination, color photography,

optical coherence tomography (OCT) and visual field

examination were carried out at each visit. Fundus

fluorescein angiography and multifocal electroretinography

(mfERG) recordings were performed

at the end of the first, third and sixth months and

anytime if necessary during the follow-up.

Results All 4 patients completed the six-month

follow-up. None of them had any systemic or ocular

complications. All of the patients experienced visual

acuity improvement, visual field improvement and

improvement in the mfERG recordings. We found

choroidal thickening in OCT of the 4 patients.

Conclusion Even though the sample size is small,

the improvements were still encouraging. Stem cell

treatment with suprachoroidal implantation of

ADMSCs seems to be safe and effective in the

treatment for optic nerve diseases that currently have

no curative treatment options.